In last month’s newsletter we asked you to share your thoughts about the FDA advisory panel’s recommendation to allow use of Dexcom CGM values for insulin dosing purposes, and how it will impact your use/interest in continuous glucose monitoring:
A. It won’t change my interest or behavior at all
B. It increases my interest in using a CGM
C. It increases the likelihood that I will use my CGM data for determining insulin doses
D. It might lead me to switch from my current CGM to a Dexcom
123 People responded. Here are the results:
Leave A Comment